Insider Transactions at United Therapeutics Corporation (NASDAQ:UTHR)

Font: Financial Modeling Prep  • Mar 16, 2026

• Martine A. Rothblatt, the Chairperson and CEO, sold 516 shares at approximately $534.99 each, leaving her with 8,414 shares.
• Ray Kurzweil, a Director, sold 4,910 shares at an average price of $489.02, reducing his holdings to 12,670 shares.
• Paul Mahon, the Executive Vice President, sold 8,300 shares at an average price of $483.16, leaving him with 36,844 shares.

United Therapeutics Corporation, listed on NASDAQ:UTHR, is a biotechnology company focused on developing and commercializing unique products to address the unmet needs of patients with chronic and life-threatening conditions. The company operates in a competitive landscape, with peers like Gilead Sciences and Amgen. United Therapeutics is known for its innovative therapies, particularly in the field of pulmonary arterial hypertension.

On March 16, 2026, Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics, sold 516 shares of the company's common stock at approximately $534.99 each. This transaction left Rothblatt with 8,414 shares. Similarly, Ray Kurzweil, a Director at United Therapeutics, sold 4,910 shares on March 4th at an average price of $489.02, reducing his holdings by 27.93% to 12,670 shares, valued at around $6.2 million.

Paul Mahon, the Executive Vice President, also executed a sale of 8,300 shares on March 5th at an average price of $483.16, totaling over $4 million. This sale marked an 18.39% reduction in his holdings, leaving him with 36,844 shares valued at approximately $17.8 million. These insider transactions are officially disclosed in documents filed with the SEC.

United Therapeutics' stock opened at $478.16 on the following Friday, reflecting a 1.4% decrease. The stock's 50-day simple moving average is $482.51, while the 200-day simple moving average is $452.28. The company has a market capitalization of approximately $21 billion, with a price-to-earnings ratio of 17.14 and a price-to-earnings-growth ratio of 1.75.

The stock has experienced a 12-month low of $266.98 and a high of $537.19. United Therapeutics has a price-to-sales ratio of about 7.38 and an enterprise value to sales ratio of around 6.89. The company's strong current ratio of 6.60 highlights its ability to cover short-term liabilities with its short-term assets. The earnings yield is approximately 5.62%, indicating the earnings generated from each dollar invested in the stock.